HUT61204A - Intranasal vaccine comprising liposome - Google Patents

Intranasal vaccine comprising liposome

Info

Publication number
HUT61204A
HUT61204A HU91256A HU25691A HUT61204A HU T61204 A HUT61204 A HU T61204A HU 91256 A HU91256 A HU 91256A HU 25691 A HU25691 A HU 25691A HU T61204 A HUT61204 A HU T61204A
Authority
HU
Hungary
Prior art keywords
liposome
intranasal vaccine
intranasal
vaccine
formulation
Prior art date
Application number
HU91256A
Other languages
English (en)
Hungarian (hu)
Other versions
HU910256D0 (en
Inventor
Haan Aalzen De
Harmen Jacob Geerligs
Jan Christiaan Wilschut
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of HU910256D0 publication Critical patent/HU910256D0/hu
Publication of HUT61204A publication Critical patent/HUT61204A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU91256A 1990-01-29 1991-01-24 Intranasal vaccine comprising liposome HUT61204A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9000207A NL9000207A (en:Method) 1990-01-29 1990-01-29

Publications (2)

Publication Number Publication Date
HU910256D0 HU910256D0 (en) 1991-08-28
HUT61204A true HUT61204A (en) 1992-12-28

Family

ID=19856496

Family Applications (1)

Application Number Title Priority Date Filing Date
HU91256A HUT61204A (en) 1990-01-29 1991-01-24 Intranasal vaccine comprising liposome

Country Status (15)

Country Link
US (1) US5756104A (en:Method)
EP (1) EP0440289B1 (en:Method)
JP (1) JP2997073B2 (en:Method)
AT (1) ATE131723T1 (en:Method)
AU (1) AU647070B2 (en:Method)
CA (1) CA2035097A1 (en:Method)
DE (1) DE69115514T2 (en:Method)
DK (1) DK0440289T3 (en:Method)
ES (1) ES2082107T3 (en:Method)
GR (1) GR3019213T3 (en:Method)
HU (1) HUT61204A (en:Method)
IE (1) IE74950B1 (en:Method)
IL (1) IL97014A (en:Method)
NL (1) NL9000207A (en:Method)
ZA (1) ZA91531B (en:Method)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4136553A1 (de) * 1991-11-06 1993-05-13 Biotechnolog Forschung Gmbh Impfstoff gegen schleimhauterreger und herstellungsverfahren
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
EP1013269A4 (en) * 1997-06-06 2002-02-20 Shionogi & Co IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
DK1031347T3 (da) * 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2003072016A2 (en) * 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
KR100958235B1 (ko) * 2001-12-19 2010-05-17 노바르티스 아게 아미노글리코시드의 폐 전달
ES2433467T3 (es) * 2005-01-20 2013-12-11 Isconova Ab Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina
ES2272178B1 (es) * 2005-09-19 2008-03-16 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano.
US20080033038A1 (en) * 2006-07-07 2008-02-07 Shytle R D Compositions of polyphenols and methods of use
SMT202000584T1 (it) * 2012-06-14 2020-11-10 Univ Bern Liposomi personalizzati per il trattamento delle infezioni batteriche
ES2442450B1 (es) * 2012-08-09 2014-12-12 Enoc Solutions, S.L. Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
WO2015031536A1 (en) 2013-08-27 2015-03-05 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4323561A (en) * 1977-09-06 1982-04-06 Temple University Of The Commonwealth System Of Higher Education Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4310550A (en) * 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
HU184141B (en) * 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4684625A (en) * 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
DE3410238A1 (de) * 1984-03-21 1985-10-03 Bayer Ag, 5090 Leverkusen Glycolipid-aehnliche substanzen in liposomenform
DE3412793A1 (de) * 1984-04-05 1985-10-17 Basotherm GmbH, 7950 Biberach Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability

Also Published As

Publication number Publication date
JPH04210925A (ja) 1992-08-03
DE69115514T2 (de) 1996-06-05
NL9000207A (en:Method) 1991-08-16
IE74950B1 (en) 1997-08-13
AU6999091A (en) 1991-08-01
EP0440289A1 (en) 1991-08-07
GR3019213T3 (en) 1996-06-30
CA2035097A1 (en) 1991-07-30
US5756104A (en) 1998-05-26
IL97014A0 (en) 1992-03-29
IE910268A1 (en) 1991-07-31
EP0440289B1 (en) 1995-12-20
ES2082107T3 (es) 1996-03-16
ZA91531B (en) 1991-10-30
AU647070B2 (en) 1994-03-17
DK0440289T3 (da) 1996-03-04
HU910256D0 (en) 1991-08-28
ATE131723T1 (de) 1996-01-15
JP2997073B2 (ja) 2000-01-11
DE69115514D1 (de) 1996-02-01
IL97014A (en) 1995-01-24

Similar Documents

Publication Publication Date Title
HUT61204A (en) Intranasal vaccine comprising liposome
IL112618A0 (en) An insulin composition and a method for the preparation thereof
GR3025184T3 (en) Vaccine composition containing adjuvants.
EP0653204A3 (en) Aerosol formulations for medical use.
HU0800468D0 (en) Medicament for inhalation, canister and device containing the same
GB8921222D0 (en) Medicinal aerosol formulations
IL101290A0 (en) Vaccine formulations
ZA914957B (en) Aerosol drug formulations
GB8907914D0 (en) Vaccine preparation
DE2964024D1 (en) Liposomes for drug delivery and composition containing a liposome drug system
EP0734710A3 (en) Medicament and support
IL78913A (en) Synthetic vaccines for foot and mouth disease,their preparation and use
IL98845A0 (en) Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
EP0462534A3 (en) Acellular anti-pertussis vaccines
EP0437729A3 (en) New peptides, procedure for their preparation and their use as a medicament, especially their use as medicament against retroviruses
IL56499A (en) Liposome medicament delivery systems,their preparation and pharmaceutical compositions containing them
EP0423238A4 (en) Synthetic vaccine against p. falciparum malaria
EP0484403A4 (en) Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines
AU3326589A (en) A synthetic vaccine against foot and mouth disease and a process for the preparation thereof
LTIP620A (en) Novel phospholipide derivatives
GR880300141T1 (en) Bacterial antigenic lysate, a process for the preparation thereof and pharmaceutical compositions containing it
ZA881337B (en) Synthetic anti-caries vaccine
EP0507435A3 (en) Improvements relating to machines for gaming, amusement and the like
EP0505608A3 (en) Alpha-dihydroergocryptine pharmaceutical preparations with neuroprotective acitivity
IL102290A0 (en) Ccv vaccine and its preparation

Legal Events

Date Code Title Description
DFA9 Temporary protection cancelled due to abandonment